Cripto monoclonal antibodies

Drug News and Perspectives

Volumn 18, Issue 5, 2005, Pages 293-303

  Hu, Xiu Feng ^a   Xing, Pei Xiang ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CRIPTO PROTEIN; EPIDERMAL GROWTH FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UO 126; WORTMANNIN;

CANCER; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; DISEASE COURSE; HUMAN; METASTASIS; NONHUMAN; ONCOGENE SRC; PHENOTYPE; PROTEIN BINDING; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 27144436201     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.5.917325     Document Type: Review

References (102)

1. Hinoda, Y., Sasaki, S., Ishida, T. and Imai, K. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 2004, 95: 621-5.
2. Cragg, M.S., French, R.R. and Glennie, M.J. Signaling antibodies in cancer therapy. Curr Opin Immunol 1999, 11: 541-7.
3. Normanno, N., Bianco, C., De Luca, A., Maiello, M.R. and Salomon, D.S. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 2003, 10: 1-21.
4. Gritsman, K., Zhang, J., Cheng, S., Heckscher, E., Talbot, W.S. and Schier, A.F. The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell 1999, 97: 121-32.
5. Salomon, D.S., Bianco, C. and De Santis, M. Cripto: A novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bioessays 1999, 21: 61-70.
6. Saloman, D.S., Bianco, C., Ebert, A.D. et al. The EGF-CFC family: Novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer 2000, 7: 199-226.
7. Qi, C.F., Liscia, D.S., Normanno, N. et al. Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer 1994, 69: 903-10.
8. Ciardiello, F., Kim, N., Saeki, T. et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA 1991, 88: 7792-6.
9. McCarty, M.F. Targeting multiple signaling pathways as a strategy for managing prostate cancer: Multifocal signal modulation therapy. Integr Cancer Ther 2004, 3: 349-80.
10. Gibbs, J.B. Mechanism-based target identification and drug discovery in cancer research. Science 2000, 287: 1969-73.
11. Nieto, M.A. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002, 3: 155-66.
12. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2: 442-54.
13. Nishihara, K. and Tsuneyoshi, M. Undifferentiated spindle cell carcinoma of the gallbladder: A clinicopathologic, immunohistochemical, and flow cytometric study of II cases. Hum Pathol 1993, 24: 1298-305.
14. Fuchs, I.B., Lichtenegger, W., Buehler, H., Henrich, W., Stein, H., Kleine-Tebbe, A. and Schaller, G. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 2002, 22: 3415-9.
15. Gilchrist, A.J., Meuser, R., Turchinsky, J., Shaw, A.R., Pasdar, M. and Dixon, W.T. Cell adhesion-mediated transformation of a human SCLC cell line is associated with the development of a normal phenotype. Exp Cell Res 2002, 276: 63-78.
16. Xue, C., Plieth, D., Venkov, C., Xu, C. and Neilson, E.G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 2003, 63: 3386-94.
17. Minchiotti, G., Parisi, S., Liguori, G.L., D'Andrea, D. and Persico, M.G. Role of the EGF-CFC gene cripto in cell differentiation and embryo development. Gene 2002, 287: 33-7.
18. Strizzi, L., Bianco, C., Normanno, N. et al. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 2004, 201: 266-76.
19. Bianco, C., Strizzi, L., Rehman, A. et al. nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 2993, 63: 1192-7.
20. Bianco, C., Kannan, S., De Santis, M. et al. Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. J Biol Chem 1999, 274: 8624-9.
21. Kannan, S., De Santis, M., Lohmeyer, M. et al. Cripto enhances the tyrosine phosphorylation of She and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem 1997, 272: 3330-5.
22. Ebert, A.D., Wechselberger, C., Frank, S. et al. Cripto-1 induces phosphatidylinositol 3′-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res 1999, 59: 4502-5.
23. Ebert, A.D., Wechselberger, C., Nees, M. et al. Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells. Exp Cell Res 2000, 257: 223-9.
24. Datta, S.R., Brunet, A. and Greenberg, M.E. Cellular survival: A play in three Akts. Genes Dev 1999, 13: 2905-27.
25. Clark, A.S., West, K., Streicher, S. and Dennis, P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1: 707-17.
26. Gray, P.C., Harrison, C.A. and Vale, W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci USA 2003, 100: 5193-8.
27. Chen, Y.G., Lui, H.M., Lin, S.L., Lee, J.M. and Ying, S. Y. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med 2002, 227: 75-87.
28. Xing, P.X., Hu, X.F., Pietersz, G.A., Hosick, H.L. and McKenzie, I.F. Cripto: A novel target for antibody-based cancer immunotherapy. Cancer Res 2004, 64: 4018-23.
29. Adkins, H.B., Bianco, C., Schiffer, S.G. et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 2003, 112: 575-87.
30. Ciccodicola, A., Dono, R., Obici, S., Simeone, A., Zollo, M. and Persico, M.G. Molecular characterization of a gene of the 'EGF family ' expressed in undifferentiated human NTERA2 teratocarcinoma cells. Embo J 1989, 8: 1987-91.
31. Minchiotti, G., Parisi, S., Liguori, G., Signore, M., Lania, G., Adamson, E.D., Lago, C.T. and Persico, M.G. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Mech Dev 2000, 90: 133-42.
32. Johnson, S.E., Rothstein, J.L. and Knowles, B.B. Expression of epidermal growth factor family gene members in early mouse development. Dev Dyn 1994, 201: 216-26.
33. Xu, C., Liguori, G., Adamson, E.D. and Persico, M.G. Specific arrest of cardiogenesis in cultured embryonic stem cells lacking Cripto-1. Dev Biol 1998, 196: 237-47.
34. Dono, R., Scalera, L., Pacifico, F., Acampora, D., Persico, M.G. and Simeone, A. The murine cripto gene: Expression during mesoderm induction and early heart morphogenesis. Development 1993, 118: 1157-68.
35. Ding, J., Yang, L., Yan, Y.T., Chen, A., Desai, N., Wynshaw-Boris, A. and Shen, M.M. Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo. Nature 1998, 395: 702-7.
36. Xu, C., Liguori, G., Persico, M.G. and Adamson, E.D. Abrogation of the Cripto gene in mouse leads to failure of postgastrulation morphogenesis and lack of differentiation of cardiomyocytes. Development 1999, 126: 483-94.
37. Niemeyer, C.C., Persico, M.G. and Adamson, E.D. Cripto: Roles in mammary cell growth, survival, differentiation and transformation. Cell Death Differ 1998, 5: 440-9.
38. Yeo, C. and Whitman, M. nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol Cell 2001, 7: 949-57.
39. Bianco, C., Adkins, H.B., Wechselberger, C. et al. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol 2002, 22: 2586-97.
40. Hay, E.D. An overview of epithelio-mesenchymal transformation. Acta Anat 1995, 154: 8-20.
41. Viebahn, C. Epithelio-mesenchymal transformation during formation of the mesoderm in the mammalian embryo. Acta Anat 1995, 154: 79-97.
42. Camus, A. and Tam, P.P. The organizer of the gastrulating mouse embryo. Curr Top Dev Biol 1999, 45: 117-53.
43. Guarino, M., Micheli, P., Pallotti, F. and Giordano, F. Pathological relevance of epithelial and mesenchymal phenotype plasticity. Pathol Res Pract 1999, 195: 379-89.
44. Thiery, J.P. and Chopin, D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 1999, 18: 31-42.
45. Wechselberger, C., Ebert, A.D., Bianco, C., Khan, N.I., Sun, Y., Wallace-Jones, B., Montesano, R. and Salomon, D.S. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res 2001, 266: 95-105.
46. Behrens, J., Weidner, K.M., Frixen, U.H., Schipper, J.H., Sachs, M., Arakaki, N., Daikuhara, Y. and Birchmeier, W. The role of E-cadherin and scatter factor in tumor invasion and cell motility. EXS 1991, 59: 109-26.
47. Hajra, K.M., Ji, X. and Fearon, E.R. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 1999, 18: 7274-9.
48. Nieset, J.E., Redfield, A.R., Jin, F., Knudsen, K.A., Johnson, K.R. and Wheelock, M.J. Characterization of the interactions of alpha-catenin with alpha-actinin and beta-catenin/plakoglobin. J Cell Sci 1997, 110(Pt 8): 1013-22.
49. Savagner, P. Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001, 23: 912-23.
50. Shibamoto, S., Hayakawa, M., Takeuchi, K., Hori, T., Oku, N., Miyazawa, K., Kitamura, N., Takeichi, M. and Ito, F. Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes Commun 1994, 1: 295-305.
51. Morkel, M., Huelsken, J., Wakamiya, M. et al. Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development 2003, 130: 6283-94.
52. Masszi, A., Di Ciano, C., Sirokmany, G. et al. Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol 2003, 284: F911-24.
53. Steinert, P.M. and Roop, D.R. Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 1988, 57: 593-625.
54. Gilles, C., Polette, M., Zahm, J.M., Tournier, J.M., Volders, L., Foidart, J.M. and Birembaut, P. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 1999, 112(Pt 24): 4615-25.
55. Normanno, N., De Luca, A., Bianco, C. et al. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol 2004, 198: 31-9.
56. Niemeyer, C.C., Spencer-Dene, B., Wu, J.X. and Adamson, E.D. Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice. Int J Cancer 1999, 81: 588-91.
57. Brandt, R., Normanno, N., Gullick, W.J. et al. Identification and biological characterization of an epidermal growth factor-related protein: Cripto-1. J Biol Chem 1994, 269: 17320-8.
58. Bianco, C., Normanno, N., De Luca, A. et al. Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. J Cell Physiol 2002, 190: 74-82.
59. Harris, R.J. and Spellman, M.W. O-linked fucose and other post-translational modifications unique to EGF modules. Glycobiology 1993, 3: 219-24.
60. Harris, R.J., van Halbeek, H., Glushka, J., Basa, L.J., Ling, V.T., Smith, K.J. and Spellman, M.W. Identification and structural analysis of the tetrasaccharide NeuAc alpha(2→6)Gal beta(1→4)GlcNAc beta(1→3)Fuc alpha 1→O-linked to serine 61 of human factor IX. Biochemistry 1993, 32: 6539-47.
61. Robinson, M.J. and Cobb, M.H. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997, 9: 180-6.
62. Kinoshita, N., Minshull, J. and Kirschner, M.W. The identification of two novel ligands of the FGF receptor by a yeast screening method and their activity in Xenopus development. Cell 1995, 83: 621-30.
63. de Bono, J.S. and Rowinsky, E.K. Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br Med Bull 2002, 64: 227-54.
64. Frame, M.C. Src in cancer: Deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002, 1602: 114-30.
65. Kenney, N.J., Huang, R.P., Johnson, G.R. et al. Detection and location of amphiregulin and Cripto-1 expression in the developing postnatal mouse mammary gland. Mol Reprod Dev 1995, 41: 277-86.
66. Herrington, E.E., Ram, T.G., Salomon, D.S., Johnson, G.R., Gullick, W.J., Kenney, N. and Hosick, H.L. Expression of epidermal growth factor-related proteins in the aged adult mouse mammary gland and their relationship to tumorigenesis. J Cell Physiol 1997, 170: 47-56.
67. Tsukita, S., Nagafuchi, A. and Yonemura, S. Molecular linkage between cadherins and actin filaments in cell-cell adherens junctions. Curr Opin Cell Biol 1992, 4: 834-9.
68. Kenney, N.J., Adkins, H.B. and Sanicola, M. nodal and Cripto-1: Embryonic pattern formation genes involved in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004, 9: 133-44.
69. Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., Gunduz, M. and Hung, M.C. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004, 6: 931-40.
70. Schiffer, S.G., Foley, S., Kaffashan, A. et al. Fucosylation of Cripto is required for its ability to facilitate nodal signaling. J Biol Chem 2001, 276: 37769-78.
71. Kumar, A., Novoselov, V., Celeste, A.J., Wolfman, N.M., ten Dijke, P. and Kuehn, M.R. Nodal signaling uses activin and transforming growth factor-beta receptor-regulated Smads. J Biol Chem 2001, 276: 656-61.
72. Gibbs, J.B. Anticancer drug targets: Growth factors and growth factor signaling. J Clin Invest 2000, 105: 9-13.
73. Wakefield, L.M. and Roberts, A.B. TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002, 12: 22-9.
74. Risbridger, G.P., Schmitt, J.F. and Robertson, D.M. Activins and inhibins in endocrine and other tumors. Endocr Rev 2001, 22: 836-58.
75. Mathews, L.S. and Vale, W.W. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991, 65: 973-82.
76. Attisano, L., Carcamo, J., Ventura, F., Weis, F.M., Massague, J. and Wrana, J.L. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75: 671-80.
77. Carcamo, J., Weis, F.M., Ventura, F., Wieser, R., Wrana, J.L., Attisano, L. and Massague, J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol Cell Biol 1994, 14: 3810-21.
78. Attisano, L., Wrana, J.L., Montalvo, E. and Massague, J. Activation of signalling by the activin receptor complex. Mol Cell Biol 1996, 16: 1066-73.
79. Derynck, R., Zhang, Y. and Feng, X.H. Smads: transcriptional activators of TGF-beta responses. Cell 1998, 95: 737-40.
80. Van, Y.T., Liu, J.J., Luo, Y., Haltiwanger, R.S., Abate-Shen, C. and Shen, M.M. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol 2002, 22: 4439-49.
81. Harrison, C.A., Wiater, E., Gray, P.C., Greenwald, J., Choe, S. and Vale, W. Modulation of activin and BMP signaling. Mol Cell Endocrinol 2004, 225: 19-24.
82. Cano, A., Perez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., del Barrio, M.G., Portillo, F. and Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000, 2: 76-83.
83. Batlle, E., Sancho, E., Franci, C., Dominguez, D., Monfar, M., Baulida, J. and Garcia De Herreros, A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000, 2: 84-9.
84. Blanco, M.J., Moreno-Bueno, G., Sarrio, D., Locascio, A., Cano, A., Palacios, J. and Nieto, M. A. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002, 21: 3241-6.
85. Schlessinger, K. and Hall, A. GSK-3beta sets Snail's pace. Nat Cell Biol 2004, 6: 913-5.
86. Dann, C.E., Hsieh, J.C., Rattner, A., Sharma, D., Nathans, J. and Leahy, D.J. Insights into Wnt binding and signaling from the structures of two Frizzled cysteine-rich domains. Nature 2001, 412: 86-90.
87. Henderson, B.R. and Fagotto, F. The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 2002, 3: 834-9.
88. Seidensticker, M.J. and Behrens, J. Biochemical interactions in the wnt pathway. Biochim Biophys Acta 2000, 1495: 168-82.
89. van de Wetering, M., Sancho, E., Verweij, C. et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111: 241-50.
90. Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B. and Polakis, P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995, 92: 3046-50.
91. Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B. and Kinzler, K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275: 1787-90.
92. Moser, A.R., Dove, W.F., Roth, K.A. and Gordon, J.I. The Min (multiple intestinal neoplasia) mutation: Its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 1992, 116: 1517-26.
93. Schatzmann, F. Marlow, R. and Streuli, C.H. Integrin signaling and mammary cell function. J Mammary Gland Biol Neoplasia 2003, 8: 395-408.
94. Maemura, M., Akiyama, S.K., Woods, V.L., Jr. and Dickson, R.B. Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells. Clin Exp Metastasis 1995, 13: 223-35.
95. Solic, N. and Davies, D.E. Differential effects of EGF and amphiregulin on adhesion molecule expression and migration of colon carcinoma cells. Exp Cell Res 1997, 234: 465-76.
96. Lynch, D.K., Ellis, C.A., Edwards, P.A. and Hiles, I.D. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene 1999, 18: 8024-32.
97. Hynes, R.O. Integrins: Bidirectional, allosteric signaling machines. Cell 2002, 110: 673-87.
98. Oloumi, A., McPhee, T. and Dedhar, S. Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta 2004, 1691: 1-15.
99. Shen, M.M. Decrypting the role of Cripto in tumorigenesis. J Clin Invest 2003, 112: 500-2.
100. Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J. and Greenberg, M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270: 1326-31.
101. Tuscano, J.M., Riva, A., Toscano, S.N., Tedder, T.F. and Kehrl, J.H. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 1999, 94: 1382-92.
102. Pedersen, I.M., Buhl, A.M., Klausen, P., Geisler, C.H. and Jurlander, J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase- dependent mechanism. Blood 2002, 99: 1314-9.